Tamoxifen

Tamoxifen

EnglishHardbackPrint on demand
Maximov Philipp Y.
Springer, Basel
EAN: 9783034806633
Print on demand
Delivery on Tuesday, 17. of December 2024
€182.18
Common price €202.42
Discount 10%
pc
Do you want this product today?
Oxford Bookshop Banská Bystrica
not available
Oxford Bookshop Bratislava
not available
Oxford Bookshop Košice
not available

Detailed information

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.

This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

EAN 9783034806633
ISBN 3034806639
Binding Hardback
Publisher Springer, Basel
Publication date August 6, 2013
Pages 199
Language English
Dimensions 235 x 155
Country Switzerland
Readership Professional & Scholarly
Authors Jordan V. Craig; Maximov Philipp Y.; McDaniel Russell E.
Illustrations XXII, 199 p. 54 illus.
Series Milestones in Drug Therapy